lanadelumab (shp643) (takhzyro) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA
AACT Drugs@FDA

Active Ingredient History

NOW
  • Now
Lanadelumab, sold under the brand name Takhzyro, is a human monoclonal antibody that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in people with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Lanadelumab is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$16557.6600 - $21551.5200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dx-2930 | lanadelumab (shp643)

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 3)

COVID-19 (Phase 3)

Healthy Volunteers (Phase 1)

Hereditary Autoinflammatory Diseases (Phase 2)

Lung Injury (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue